SPARC
Update in progressSPARC.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company based in Mumbai, India, active in research and development for India and international markets. Its focus is oncology and immunology, with programs including Vodobatinib (SCO-088), a BCR-ABL inhibitor in phase 2 for refractory chronic myeloid leukemia; Vibozilimod (SCD-044), an S1PR1 agonist in phase 2 for psoriasis and atopic dermatitis; SCD-153 for alopecia areata; and SBO-154, an anti-MUC-1 ADC in preclinical development. Incorporated 2006.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.35
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.17
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.20
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!